Business Context and Reporting Period
Company: CorVel Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2005
Business Overview: CorVel is an independent nationwide provider of medical cost containment and managed care services, primarily for workers' compensation, auto insurance, and group health policies. Services include automated medical fee auditing, preferred provider networks (PPO), utilization review, and patient management. The company operates in one reportable segment: managed care.
Key Financial Metrics (Fiscal Year 2005)
| Metric | 2005 | 2004 | Change |
|---|---|---|---|
| Revenues | $291.0 million | $305.3 million | (4.7%) |
| Cost of Revenues | $246.3 million | $253.8 million | (3.0%) |
| Gross Profit | $44.7 million | $51.4 million | (13.1%) |
| Gross Margin | 15.3% | 16.8% | -150 bps |
| Net Income | $10.2 million | $16.0 million | (36.6%) |
| Diluted EPS | $0.97 | $1.48 | (34.5%) |
| Cash & Equivalents | $8.9 million | $8.6 million | +3.5% |
| Working Capital | $39.2 million | $41.2 million | (4.9%) |
| Total Debt | $0 | $0 | N/A |
Liquidity: The company maintains a $10 million line of credit (increased from $5 million in March 2005) with no borrowings outstanding as of March 31, 2005. The company is in compliance with all loan covenants.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by $14 million (4.7%) compared to fiscal 2004. The decline was driven by a reduction in patient management referrals (due to a soft national labor market and increased employer workplace safety programs) and decreased demand for network solution services (specifically Independent Medical Examinations and MRI services).
- Margin Compression: Gross margin decreased from 16.8% to 15.3%. This was partially due to the revenue mix shift toward lower-margin services and the impact of the CorCareRX pharmacy program, which has lower gross margins than other network solutions.
- Expense Management: Cost of revenues decreased by $8 million (3.3%), aided by a reduction in field employee headcount and lower direct costs for MRI and prescription drug services. However, General and Administrative (G&A) expenses increased by $2 million (7.7%) to $28.1 million, primarily due to increased technology investments and depreciation/amortization.
- Stock Repurchases: The company spent $17.2 million to repurchase 691,720 shares of common stock in fiscal 2005, increasing the cumulative repurchase total to 6,265,148 shares (approx. 38% of outstanding stock) at a cost of $113.5 million since 1996.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Outlook
Management notes that the environment for revenue and margin growth is difficult due to flat-to-declining market conditions, price competition, and legislative changes in workers' compensation laws. The company continues to invest in technology (MedCheck enhancements, scanning services) to improve efficiency and maintain competitive advantage.
Material Weakness in Internal Controls
Critical Issue: Management and the independent auditor (Grant Thornton LLP) identified a material weakness in internal control over financial reporting as of March 31, 2005. Consequently, the auditor issued a disclaimer of opinion on the effectiveness of internal controls.
- Causes: Insufficient financial accounting resources, inadequate documentation of controls, reliance on detective rather than preventive controls, and inadequate controls over the financial reporting close process and system access rights.
- Remediation: Management plans to dedicate staffing for control documentation, increase oversight of regional accounting, and implement expanded automated testing.
Risk Factors
- Regulatory Changes: Changes in state workers' compensation laws (e.g., California's Medical Provider Networks) could reduce demand for services or increase operational costs.
- Competition: Increased competition from larger insurance carriers and HMOs offering in-house services.
- Market Dynamics: Declines in workplace injury rates and the shift toward early intervention services may reduce the volume of claims requiring later-stage management services.
- Accounting Changes: Implementation of SFAS 123(R) regarding stock-based compensation (effective June 2006) is expected to materially reduce reported earnings.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of management's plan to remediate the material weakness in internal controls and whether future audits will result in an unqualified opinion on internal controls.
- Revenue Trend: Monitor quarterly revenue trends to determine if the decline in patient management referrals and network solution demand is stabilizing or accelerating.
- Margin Pressure: Assess whether the company can reverse the gross margin compression trend through operational efficiencies or pricing power.
- Regulatory Impact: Evaluate the specific impact of new state legislation (particularly in California) on the company's service demand and cost structure.
- Stock-Based Compensation: Review the projected impact of SFAS 123(R) adoption on future net income and EPS starting in fiscal 2006.